『Eczema Breakthroughs』のカバーアート

Eczema Breakthroughs

Eczema Breakthroughs

著者: Global Parents for Eczema Research (GPER)
無料で聴く

このコンテンツについて

Interviews with the leading scientists and innovators, hosted by Global Parents for Eczema Research (GPER), a non-profit led by parents of children with eczema. Like what we're doing? Consider donating to GPER at: www.parentsforeczemaresearch.com/donate Do you enjoy this podcast? Rate it on Apple Podcasts, Google Podcasts or Spotify! Learn more about GPER and subscribe to this podcast at: parentsforeczemaresearch.orgCopyright 2025 Global Parents for Eczema Research (GPER) 人間関係 子育て 生物科学 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Staph’s secret superpower and their accomplice Streptococcus
    2025/05/22

    Two new studies from the Society for Investigative Dermatology (SID) conference reveal how Staph bacteria use clever strategies to disarm the skin's barrier maintenance function and work with other bacteria to amplify inflammation. Join us for an interview with Dr. Nathan Archer and Dr. Laine Feller from John Hopkins School of Medicine who explain how Staph aureus bacteria uses its superantigen superpower to hinder lipid production ... and more new research from this year's SID meeting.

    続きを読む 一部表示
    14 分
  • New nonsteroidal eczema cream approved for kids
    2025/04/30

    New treatment alert! The FDA recently approved Tapinarof, applied as a cream, for kids 2 years and up. We ask Dr. Leon Kircik from Icahn School of Medicine, NY, who led the clinical trials about the safety, efficacy and side effects of Tapinarof. And because we are parents too, we ask: How quickly does it work? Can you start/stop it as needed? How easy will it be to access? And more. If you like our podcast, please consider supporting it with a tax deductible donation.

    Research discussed

    Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

    Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis

    Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials

    Tapinarof cream in the treatment of atopic dermatitis in children and adults a systematic review and meta-analysis

    Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs

    続きを読む 一部表示
    22 分
  • Hot off the press - What researchers are talking about at AAAAI Allergy Conference.
    2025/03/20

    What to look out for in eczema moisturizers, why eczema babies have rosy red cheeks and can allergies transfer to baby from breast milk? Join Korey Capozza, Dr. Jessica Hui-Beckman (National Jewish Health) and Dr. Kirsi Jarvinen-Seppo (University of Rochester) to find the answers. If you like our podcast, please consider supporting it with a tax deductible donation.

    Research discussed

    Consumer Preferences, Product Characteristics, and Potentially Allergenic Ingredients in Best-selling Moisturizers

    Early Life Cheek Skin Barrier Changes are Associated with Atopic Dermatitis Development

    Prevention of IgE-Mediated Food Allergy: Emerging Strategies Through Maternal and Neonatal Interventions


    続きを読む 一部表示
    17 分

Eczema Breakthroughsに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。